Drug Profile
Omalizumab - Genentech/Novartis
Alternative Names: Anti-IgE monoclonal antibody E25; E 25; IgE 025; Monoclonal antibody E25; Olizumab; Recombinant human monoclonal antibody E25; RG-3648; rhuMAb 25; rhuMAb E25; XolairLatest Information Update: 01 Apr 2024
Price :
$50
*
At a glance
- Originator Genentech
- Developer Dana-Farber Cancer Institute; Genentech; John Hopkins University; National Institute of Allergy and Infectious Diseases; Novartis
- Class Antiallergics; Antiasthmatics; Monoclonal antibodies; Skin disorder therapies
- Mechanism of Action IgE receptor antagonists; Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Allergic asthma; Chronic urticaria; Nasal polyps
- Registered Food hypersensitivity; Peanut hypersensitivity; Seasonal allergic rhinitis
- Phase II/III Mastocytosis
- Phase II Asthma; Nephritis
- No development reported Hypersensitivity
Most Recent Events
- 23 Feb 2024 Efficacy and adverse events data from a phase III OUTMATCH trial in Food hypersensitivity and Peanut hypersensitivity presented at the 2024 American Academy of Allergy, Asthma & Immunology (AAAAI-2024) Annual Meeting (AAAAI-2024)
- 16 Feb 2024 Registered for Food hypersensitivity (In adolescents, In children, Adjuvant therapy, In adults) in USA (SC) (NCT03881696)
- 16 Feb 2024 Registered for Food hypersensitivity (In adolescents, In children, Monotherapy, In adults) in USA (SC) (NCT03881696)